Screener
Eligibility screening
Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
25 US sites in CA, FL, GA, IN +11
Before we begin
Who are you filling this out for?
Your answer affects how the questions are phrased.